A
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corbus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corbus Pharmaceuticals was filed on June 26, 2024 so you should expect the next rating to be made available sometime around June 26, 2025.
A
While ratings are subjective and will change, the latest Corbus Pharmaceuticals (CRBP) rating was a initiated with a price target of $0.00 to $85.00. The current price Corbus Pharmaceuticals (CRBP) is trading at is $44.63, which is within the analyst’s predicted range.
